# Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer

> **NCT05975749** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 114 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** Trastuzuma
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT05975749
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2026-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05975749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05975749, "Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05975749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*